New Technologies News Today

stephen cave, welcome to hardtalk. thank you for having me. its a great pleasure. you believe that our human awareness of our own mortality is absolutely central to the human story. why? well, all creatures strive to live on, to keep going. they would not be around us any more if they did not. they wouldnt be around us any more if they didnt. the mouse that didnt care about surviving wouldnt pass on its genes. so we come for from a long line of creatures that are determined to keep goi...

which is straight after this programme. welcome to hardtalk. im stephen sackur. one of the key drivers of human thought and behaviour throughout history has been knowledge of our own mortality. from childhood each of us knows we will die. religion, philosophy and science all wrestle with that fact and have in different ways embraced the quest for immortality. my guess today, stephen cave, director of the cambridge institute for technology and humanity is at the centre of a growing deba...

5G Advanced is the next overhaul of cellular communications, and one thing included is a means for spatial audio over voice and video calls. What?

In the state policy of Turkmenistan, an ecological aspect is closely co-ordinated with its social and economic component and is integrated into large-scale programs and infrastructural projects. At that, a great significance is given to popularisation ...

Nokia (NOK) has successfully demonstrated the "world's first cellular call using new Immersive Voice and Audio Services or IVAS" codec, making a breakthrough in voice communication technology.

ESPOO (dpa-AFX) - Nokia (NOK) has successfully demonstrated the 'world's first cellular call using new Immersive Voice and Audio Services or IVAS' codec, making a breakthrough in voice communication

Lundmark was famously on hand back in 1991 when the Finnish phone giant conducted the first commercial call using the global system for mobile communications, or GSM...

Impressive powertrain, battery, and electronics updates aim to keep Rivian ahead of the pack.

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with previously treated PD-L1-positive metastatic...

Initial data from the ongoing Phase 2 trial showed a 12-month overall survival rate of 69% and a median overall survival of 17.5 months in patients with...